Access cutting-edge i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. treatment through this clinical trial at a research site in Scottsdale. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Scottsdale location
Access i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. treatment provided free
Check if you qualify for this i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. clinical trial in Scottsdale, AZ
No-Cost Study Care
Local to Scottsdale
Convenient for AZ residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.
Sponsor: Simcha IL-18, Inc.
Yes, this clinical trial (NCT04787042) has an active research site in Scottsdale, AZ that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. treatment options in Scottsdale, AZ, this clinical trial (NCT04787042) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Scottsdale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all i cannot determine the primary medical condition from the provided information. the study title only mentions "st-067" (which appears to be an investigational drug), and the conditions listed contain only drug/treatment names (st-067, obinutuzumab, and pembrolizumab) rather than medical conditions. the brief summary field appears to be incomplete. without information about the actual disease or condition being treated, i cannot extract a patient-facing medical condition. clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Scottsdale — not just this study.
Browse Multiple Myeloma Trials in Scottsdale →